Michele Holcomb Acquires 93,944 Shares of PureTech Health (LON:PRTC) Stock

PureTech Health plc (LON:PRTC) insider Michele Holcomb bought 93,944 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was purchased at an average price of GBX 1 per share, with a total value of £939.44.

Michele Holcomb also recently made the following trade(s):

• On Wednesday, July 8th, Michele Holcomb acquired 31,481 shares of PureTech Health stock. The stock was acquired at an average price of GBX 119 per share, for a total transaction of £37,462.39.

PureTech Health Stock Performance

Shares of PRTC traded down GBX 0.48 during mid-day trading on Friday, reaching GBX 119.12. The company’s stock had a trading volume of 512,639 shares, compared to its average volume of 1,072,302. PureTech Health plc has a 1-year low of GBX 104.71 and a 1-year high of GBX 146.40. The stock has a market cap of £289.96 million, a P/E ratio of -2.59 and a beta of 0.79. The business has a 50-day simple moving average of GBX 127.71 and a two-hundred day simple moving average of GBX 126.71. The company has a current ratio of 6.59, a quick ratio of 2.51 and a debt-to-equity ratio of 6.33.

Analyst Upgrades and Downgrades

Separately, Peel Hunt reaffirmed a “buy” rating and set a GBX 508 price target on shares of PureTech Health in a report on Monday, July 13th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of GBX 508.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.